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ABSTRACT
Objectives: To compare the success of two controlled ovarian hyperstimulation protocols; 
rFSH + hp-hMG with only rFSH in the GnRH antagonist protocol in diminished ovarian 
reserve under 35 years of age. 
Material and methods: Data from January 2015 to June 2019 were abstracted from the 
hospital records of IVF Clinic. The women younger than 35 years of age who were diagnosed 
as diminished ovarian reserve and underwent standard GnRH antagonist protocol were 
included. Patients in Group-1 underwent controlled ovarian stimulation with rFSH alone and 
Group-2 with rFSH in combination with hp-hMG. Patients in both groups were divided into 
three subgroups according to their antral follicle count at Day 3: < 4 (a), 4–6 (b), and 7–10 
(c). Demographic features and IVF outcomes of the patients were extracted.
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Results: Total number of retrieved oocytes, was higher in Group-1 than Group-2 (6.5 ± 2.1 vs
5.5 ± 2.3, respectively, p < 0.001). However, there were no significant differences between the
two groups in terms of clinical pregnancy rate, implantation rate, miscarriage rate and live 
birth rate. Although the main study outcome parameters did not show significant difference 
between Group-1a and Group-2a, the number of mature oocytes (5 ± 2.8 vs 1.8 ± 1.2, 
respectively, p = 0.006) was higher in Group-1a.
Conclusions: We observed no beneficial effect of LH supplementation during IVF for the 
treatment of women under 35 years old with diminished ovarian reserve in the first treatment 
cycle when compared with rFSH only in the antagonist protocols.
Key words: diminished ovarian reserve; GnRH antagonist; luteinizing hormone; ovarian 
hyperstimulation
INTRODUCTION
An adequate ovarian response to controlled ovarian stimulation (COS) is crucial for 
the success of assisted reproductive technology (ART). Follicle-stimulating hormone (FSH) 
and luteinizing hormone (LH) are known to play pivotal roles in folliculogenesis. Although 
LH is required in the follicular phase to ensure both follicular estradiol (E2) production 
necessary for completion of oocyte maturation and endometrial preparation for implantation, 
treatment with FSH alone generally leads to successful development and maturation of 
follicles during in vitro fertilization (IVF) cycles [1–3]. Some recent studies suggested that 
LH supplementation at the mid-follicular phase of controlled ovarian stimulation during IVF 
treatment might improve pregnancy rates, however this topic is still debatable, as the data 
from different studies is conflicting. Gonadotropin agonists or antagonists are used to 
suppress the pituitary secretion of gonadotropins and to have a complete control of the 
follicular phase of the treatment cycle with administration of exogenous gonadotropins. These
agonist and antagonist regimens aim to prevent early luteinization of the follicle by 
suppression of an early LH rise. During the last decade, the use of GnRH antagonist protocols
provides the opportunity to control the endogenous LH surge in a rapid and more convenient 
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way and thereby cause immediate suppression of gonadotrophin release without the so-called 
flare-up effect. Previous studies investigated the role of LH supplementation in GnRH 
agonists protocols in IVF-ET treatment cycles [3–5]. However, the efficacy of LH support in 
GnRH antagonist protocols is still unclear.
Although FSH alone can induce follicular growth, based on the 'two cell two 
gonadotropin' theory'; presence of LH in the follicular phase of a natural cycle is important for
production of estradiol. Estradiol is secreted by FSH stimulation in granulosa cells from the 
androgenic precursors secreted from the theca cells in response to LH stimulation.  Moreover, 
LH has a role in the resumption of meiosis and in production of progesterone following 
ovulation in order to sustain the integrity of the endometrium. In normogonadotropic women, 
although the pituitary gland LH and FSH secretion is down-regulated by gonadotropin agonist
or antagonist administration, r-FSH alone leads to acceptable ovarian stimulation as residual 
LH is adequate for its pivot role in follicular growth and stimulation. Therefore, stimulation 
with rec-FSH alone or HMG has similar implantation and pregnancy rates [6]. 
There are also conflicting opinions regarding the specific patient group that can benefit
from LH supplementation in ART cycles [2]. In recent years, there has been a significant 
increase in the number of young patients with diminished ovarian reserve (DOR) who apply 
for an IVF-ET treatment. 
Objectives
The effect of LH supplementation during controlled ovarian hyperstimulation in 
IVF/intracytoplasmic sperm injection (ICSI) cycles in women over 35 years of age who have 
DOR have been studied [1, 7]. However, there have been limited studies on the use of LH in 
IVF/ICSI cycles in the treatment of women with DOR under 35 years of age. Therefore, in 
this study, we compared the success of two controlled ovarian hyperstimulation protocols; 
recombinant follicle-stimulating hormone (rFSH) + highly purified human menotropin (hp-
hMG) with only rFSH in the GnRH antagonist protocol in poor responders under 35 years of 
age. 
MATERIAL AND METHODS
This study was conducted as a retrospective trial in the IVF Clinic of the University of 
Health Sciences School of Medicine, Etlik Zubeyde Hanım Research and Training Hospital, 
Ankara, Turkey, between January 2015 and June 2019. The study protocol was approved by 
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the hospital’s Ethics Committee (N: 90057706-799). Informed consent was obtained from all 
participants. 
The women younger than 35 years of age who were diagnosed as DOR and underwent
standard GnRH antagonist protocol were included in the study. DOR was defined as having 
one of the criteria defined below: antral follicle count (AFC) < 11, Antimüllerian Hormone 
(AMH) < 1.1 ng/mL and number of collected oocytes < 7 [4, 7]. The exclusion criteria were 
being a normo-responder, high responders or ≥ 35 years old poor responder or having a body 
mass index (BMI) ≥ 30 or organic lesion of the endometrium or uterus, patients with ovarian 
cyst or ovarian surgery, patients with grade 3–4 endometriosis, uterine abnormality, or a 
history of radiotherapy and chemotherapy. 
All patients were scheduled for their first ICSI-embryo transfer (ET) cycles. Patients in
Group-1 underwent controlled ovarian stimulation with rFSH (Gonal-F; MerckSerono, SA, 
Geneva, Switzerland) alone and Group-2 with rFSH (Gonal-F; MerckSerono, SA, Geneva, 
Switzerland) in combination with hp-hMG (Merional, IBSA, Switzerland). Due to the 
different clinical approaches of clinicians in our clinic, hp-HMG was added to some DOR 
patients under the age of 35 starting from the first day of their treatment. Patients in both 
groups were divided into three subgroups according to their AFC at Day 3: < 4 (a), 4–6 (b), 
and 7–10 (c).
Data of the patient groups; age, body mass index (BMI), total dose of rFSH and rLH 
administered, duration of induction, serum E2 levels and progesterone at hCG administration, 
number of follicles < 11 mm, number of total follicles and number of follicles measuring >16 
mm at hCG administration, endometrial thickness at retrieval, total number of oocytes 
retrieved, numbers of mature oocytes (MII); number of oocytes fertilized, number of embryos 
obtained were extracted from the electronic patient files.
For all participants, baseline ultrasound scan and blood tests were performed on day 
2–3 of the menstrual cycle. Ovarian stimulation with gonadotropins was commenced with a 
dose of 225–400 IU, and subjects were monitored every 2–4 days by transvaginal ultrasound 
scan (TVUS) (Logiq A5; General Electric, Milwaukee, WI) performed by the same physician 
starting on day five of ovarian hyperstimulation. GnRH antagonist (0.25 mg/Day of Cetrotide;
Merck-Serono, Darmstadt, Germany) was initiated when the leading follicle reached 13–14 
mm on TVUS or when the serum E2 level was > 400 ng/mL. Cycle cancelation was defined 
as lack of follicular development (no follicles of at least 12 mm after eight days of treatment 
and endometrial thickness < 4 mm) and/or a clinically significant decrease in serum E2 level 
in two consecutive days during the ovarian stimulation period. When at least three follicles 
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reached a mean diameter of ≥ 18 mm, 250 μg of recombinant human chorionic gonadotropin 
(rHCG) (Ovitrelle; Merck Serono, Germany) or 10000 IU of urinary HCG (Pregnyl; 
Schering-Plough, Turkey) was administered. Transvaginal ultrasound-guided oocyte retrieval 
was performed 35.5 hours after HCG administration. Oocyte pick-up was performed under 
general anesthesia. The oocytes were inseminated by ICSI. The luteal phase was supported 
with progesterone vaginal gel (90 mg/d, Crinone 8% Vaginal Gel; Merck-Serono, Vevey, 
Switzerland) twice a day after oocyte pick-up and continued in pregnant patients until 12 
weeks of gestation. 
The primary endpoints of the study were implantation rate (IR; positive β-hCG test ≥ 
10 IU, 10 days after embryo transfer), clinical pregnancy rate (CPR) (determination of 
embryonic heartbeat on TVS was defined as clinical pregnancy), miscarriage rate (MR; 
pregnancy loss before 24 weeks of gestation) and live birth rate (LBR; delivery of a viable 
infant after 24 weeks of gestation). Secondary outcomes were the total number of retrieved 
oocytes, the number of mature oocytes and number of good-quality embryos.
Statistics
Statistical analyses were performed using SPSS (version 20; SPSS, Chicago, IL). Data are 
expressed as the average ± SD or percentage. The variables were investigated using visual 
(histograms, probability plots) and analytical methods (Kolmogorov–Smirnov/Shapiro–Wilk 
test) to determine whether they were normally distributed. The Mann–Whitney U-test was 
used for non-parametric numerical data, and Student’s t-test was used for parametric data. 
Categorical data were compared using the Chi-square test or Fisher’s exact test. In all 
analyses, P < 0.05 was taken to indicate statistical significance.
RESULTS
During the study period a total of 393 women under age 35 who were diagnosed as 
DOR were treated at our institution; 119 consecutive patients treated with rFSH (Group-1) 
and 274 consecutive patients receiving rFSH + hp-hMG treatment (Group-2) were included in
the study. Patients’ demographic characteristics and ovarian stimulation cycle outcomes are 
shown in Table 1. Demographic parameters (age, BMI, and parity) were similar in the two 
groups. Duration of ovarian stimulation (9.4 ± 2 vs 8.6 ± 1.9 days, respectively, p < 0.001), 
total dose of gonadotropins administered (2738.3 ± 989.4 vs 1913.1 ± 575.1 IU, respectively, 
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p < 0.001) were higher in Group-2 in comparison to Group-1. In contrast, basal LH (5.5 ± 3.2 
vs 5.1 ± 3.5, respectively, p < 0.001), and E2 level on hCG day (1620.1 ± 1006.7 vs 1279.9 ± 
673, respectively, p = 0.001) were higher in group-1 in comparison to Group-2. Basal FSH 
(10.1 ± 7 vs 10.7 ± 3.1, respectively, p = 0.980), Basal E2 (47. ± 26.5 vs 48.7 ± 49.6, 
respectively, p: 0.267), AFC (7.0 ± 2.7 vs 7.5 ± 2.1, respectively, p: 0.647), AMH (0,4 ± 0.1 
vs 0.3 ± 0.2, respectively, p: 0.645) levels were similar in the two groups (Table 1). 
The main study outcome total number of retrieved oocytes, was higher in Group-1 (rFSH 
group) than Group-2 (6.5 ± 2.1 vs 5.5 ± 2.3, respectively, p < 0.001) (Tab. 1, Fig. 1). There 
were no significant differences between the two groups in terms of CPR, IR, MR, LBR and 
multiple pregnancy rate (twins) (Tab. 1). 
The main data set was analyzed according to different ranges of AFC, i.e., <4 
(subgroup a), 4–6 (subgroup b), and 7–10 (subgroup c) (Tab. 2). The majority of both 
laboratory clinical and clinical outcome measures were comparable in subgroup c (AFC 7-
10), regardless of the stimulation regimen (Group-1c and Group-2c), but in this subgroup the 
percentage of the total number of retrieved oocytes was moderately higher in Group-1c than 
Group-2c (6.5 ± 2.2 vs 6.3 ± 1.9, respectively, p:0.014). In addition, total gonadotropin doses 
in Group-2c (2775.2 ± 953.4 vs 2040.4 ± 548.7, respectively, p < 0.001) were higher, and E2 
values on HCG Day (1447.7 ± 564.6 vs 1794.5 ± 1075.1, respectively, p = 0.003) were lower 
than Group-1c.
In women with AFC within the range of 4–6 (subgroup b), the total number of 
retrieved oocytes (6.5 ± 1.7 vs 4.4 ± 2.3, respectively, p = 0.049) and the number of mature 
oocytes (4.5 ± 2.6 vs 3.2 ± 1.9, respectively, p = 0.044) were also higher in Group-1b in 
comparison to Group-2b. In addition, the patients in Group-2 had similar AMH, however 
significantly higher duration of treatment (9.3 ± 2 vs 9 ± 1, respectively, p < 0.001) and total 
gonadotropin dose (2826.4 ± 928.1 vs 2415 ± 984.2, respectively, p < 0.001) in Group-2b. 
There were no marked differences between Group-1a and Group-2a (women with AFC <4). 
Although the main study outcome parameters did not show significant difference between 
Group-1a and Group-2a, the number of mature oocytes (5 ± 2.8 vs 1.8 ± 1.2, respectively, 
p:0.006) was higher in Group-1a.
DISCUSSION
GnRH antagonist regimens have been widely used in recent years as these regimens 
are flexible and have a shorter duration of gonadotropin administration. GnRH antagonists 
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down-regulate LH secretion rapidly, but in a reversible manner.  The promoting effect of 
premature high LH levels on follicular atresia is more established yet, the treshold LH level 
that will support follicular growth without promoting follicular atresia is not quite clear [8, 9].
LH supplementation in patients with suboptimal response have been proposed in order to 
improve IVF-ET outcome.  Although many different protocols and strategies have been 
proposed for enhancement of the outcome in these patients, there is no consensus on the ideal 
treatment regimen [10]. 
Younger women with low ovarian reserve represent one of the most difficult groups to 
treat, so the administration of ideal gonadotropin protocol is especially important for this 
group. Several attempts have been made to improve clinical outcomes, such as increasing the 
initial dose of rFSH or using different GnRH analogs or supplementation of standard FSH 
treatment with LH/hMG [11]. Despite some overlap among studies, conflicting results have 
been reported. Alviggi et al., [12] reported that LH supplementation might be beneficial in 
patients with adequate pre-stimulation ovarian reserve parameters that show an unexpected 
low response to FSH monotherapy and women with an age range of 36 to 39. Alviggi et al., 
reported no significant success with addition of LH in DORs patients defined according to the
Bologna criteria. In a meta-analysis [8], a significantly higher clinical pregnancy (odds ratio: 
2.03, p = 0.003), implantation rate (odds ratio: 2.62, p = 0.004) and number of oocytes 
retrieved (weight mean difference: 1.98, p = 0.03) was achieved in hypo-responders 
supplemented with recombinant LH (rLH) when compared with DOR patients undergoing 
FSH monotherapy. However, the heterogeneity of the patients included in the studies 
reviewed makes it difficult to determinate the characteristic of women who would benefit 
from LH supplementation. The presented study demonstrated that addition of hp-hMG to 
rFSH on the day of gonadotropin administration had no significant effect on implantation rate,
clinical pregnancy rate or live birth rates using the flexible GnRH antagonist protocol in 
women with DOR aged under 35 years. In addition, the total gonadotropin dose was lower in 
patients receiving only rFSH in all subgroups.
Although most recent publications have shown that LH supplementation to FSH 
makes measurable differences in clinical practice [8, 11, 12], the study by Vuong et al., [1] 
showed different results as LH supplementation to FSH using a GnRH antagonist protocol 
had no significant effect on the total number of retrieved oocytes, mature oocytes, 
implantation rate, clinical pregnancy rate or live birth rate in women aged ≥ 35 years. In 
contrast, in our study, total numbers of retrieved and mature oocytes were even higher in the 
rFSH group in women < 35 years with DOR. However, although the number of good-quality 
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embryos was better in the rFSH group, implantation rates were similar. The difference results 
obtained by Vuong et al. [1], might be related to the recruitment of patients with better 
prognosis as women with AFC >10 were also included in the study group, and the mean AMH
was 1.6. 
In a similar study in which patients under the age of 35 were also evaluated [13], retrieved 
and mature oocyte counts were similar in patients who received rFSH only and rFSH + hp-
hMG, but implantation and clinical pregnancy rates were higher in the rFSH + hp-hMG 
group. The participants included in this study had an age range of 19 to 42 and unlike the 
presented study the study group was not restricted to a hypo-responder group. 
Similar to the Voung’s study [1], the number of cancelled cycles was lower in patients 
with LH supplementation in our study group. Our finding of significantly higher levels of 
estradiol in patients receiving rec-FSH only, supports the hypothesis that states that 
endogenous serum LH level at the late-follicular phase is sufficient even if a GnRH antagonist
have been started. Younnis et al. [14], supplemented LH on the day of hCG trigger but failed 
to demonstrate any difference in E2 levels when compared to the levels without LH 
supplementation in antagonist cycles in women < 35 years of age and/or had a previous low 
ovarian response. According to the findings of the presented study, it can be speculated that 
the total number of retrieved oocytes and mature oocyte counts of the patients in the rFSH 
group was high due to the higher E2 levels. Contrarily, progesterone (P) levels on hCG day 
were similar in two groups, in concordance with other published studies [13, 15].  Bosch et 
al., [16] found a high P level on hCG administration day in all patients without LH 
supplementation and reported a significant increase in implantation rate after LH 
supplementation in patients aged between 35–39 years while there was no impact of LH 
supplementation in patients < 35 years of age. 
Another controversial issue is determining when to starting LH supplementation and 
several different treatment approaches have been reported. In some studies, showing a 
positive effect of the addition of LH on clinical pregnancy rates in patients over 35 years old 
[1, 15], rec-LH was administrated after the sixth day considering the activation of LH 
receptors. In another review [8], LH supplementation started at the mid-follicular phase in 
hypo-responder patients > 35 years of age had a positive effect on ART results. Also, younger 
women (aged 20–36 years) were shown to produce higher quality embryos after addition of 
rLH to rFSH treatment on the first day of the GnRH antagonist stimulation protocol [17]. On 
the other hand, there are some reports [18] showing that LH supplementation increases the 
implantation rate independent from the age of the patient. In the current study, LH was added 
8
to FSH in the form of hp-hMG starting from the first day of the treatment, but significantly 
more high-grade embryos were observed in the rFSH group.  A recent study showed that [19],
despite severe limitations, antagonist administration given to selected patients did not have an 
impact on cycle cancellation rates, the incidence of early luteinization, and overall, ART 
outcomes. As in many clinics, antagonist administration and LH supplementation are initiated 
regardless of the serum LH measurements. A better approach might be measuring the LH 
values of the patients and only deciding about LH supplementation   if required after finding a
threshold value of LH for good IVf outcome. 
Unlike other studies, total gonadotropin doses and days of stimulation were lower in 
patients receiving rFSH in all subgroups. Especially in the subgroup a and b, although clinical
pregnancy rates were similar, total gonadotropin doses were lower in the rFSH group. On the 
other hand, the greater number of follicles > 17 mm in the FSH group was indicative of a 
higher number of retrieved oocytes. Therefore, more oocytes were collected with a lower dose
of gonadotropin and with a shorter period of stimulation. In this patient group, only rFSH 
treatment seemed to be more advantageous in terms of cost-effectiveness. The data of patients
under 35 years of age in a recent study [16] supported our findings. Hypo-responsiveness to 
gonadotropin stimulation in the patient group with poor response has been suggested to be 
linked with genetic mutations or single nucleotide polymorphisms (SNPs) of endogenous 
gonadotropin receptors and these patients may demonstrate an ovarian sensitivity to 
exogenous gonadotropins [8]. 
Among the strengths of the present study was the selected patient group as although 
the efficacy of adding LH to treatment that appears to be beneficial for the treatment of 
women with DOR in GnRH agonist protocols has been investigated by many authors [4, 20, 
21], there are few studies with antagonist protocols in women under 35 years old with a 
diminished ovarian reserve. The similarity of basal E2, AFC and AMH of the two groups 
increases the validity of the comparison and the interpretation of the data, increasing the 
strength of our result.
Inclusion of patients receiving their first treatment cycle is the other strength of the 
study. Moreover, dividing participants into subgroups based on AFCs reduced bias in our 
definition of DOR. On the other hand, if the number of participants in groups 1a and 1b had 
been higher, maybe our results might be more significant. The most important limitations of 
our study are its retrospective design and the use of hMG that has an LH activity derived from
hCG rather than LH. Therefore, some authors [12] have not evaluated hMG in their reviews. 
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CONCLUSIONS
We observed no beneficial effect of LH supplementation during COS for the treatment
of women under 35 years old with DOR in the first treatment cycle when compared with 
rFSH only in the antagonist protocols. Randomized control trials focusing specifically on 
young patients affected by DOR who received antagonist protocols are required for a final 
decision.
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Table 1. Demographic characteristics and ovarian stimulation outcomes
recFSH recFSH+HMG
119 (30.3%) 274 (69.7%) p
Age (Years) 29.3 ± 3.1 29.6 ± 3.3 0.316
BMI (kg/m2) 27.7 ± 5.2 27.1 ± 5.2 0.352
Basal FSH (IU/L) 10.7 ± 3.1 10.1 ± 7 0.980
Basal LH (IU/L) 5.5 ± 3.2 5.1 ± 3.5 0.047
Basal E2 (pmol/L) 47. ± 26.5 48.7 ± 49.6 0.267
AFC 7.0 ± 2.7 7.5 ± 2.1 0.647
AMH 0,4 ± 0.1 0.3 ± 0.2 0.645
Days of stimulation 8.6 ± 1.9 9.4 ± 2 <0.001
Total gonadotropin dose (IU) 1913.1 ± 575.1 2738.3 ± 989.4 <0.001
E2 value on HCG day (pmol/L)
1620.1 ±
1006.7
1279.9 ± 673 0.001
P value on HCG day (pmol/L) 0.9 ± 0.4 1.2 ± 2.9 0.252
Endometrial thickness (mm) on 
HCG day 
9.7 ± 2 9.9 ± 2.1 0.518
Number of follicles ≥ 17 mm in 
diameter on HCG day
         2.8±2        2.1±1.5 0.005
Number of follicles 15–17mm in         2.6±2.5        1.9±1.6 0.038
13
diameter on HCG day
LH value on OPU day(pmol/L) 3.2 ± 4.3 3.4 ± 4.0 0.996
No. of retrieved oocytes 6.5 ± 2.1 5.5 ± 2.3 <0.001
No. of mature oocytes 4.9 ± 2.2 4.1 ± 2.2 0.005
Fertilization rate 0.5 ± 0.3 0.5 ± 0.3 0.764
No. of 2PN 2.8 ± 1.7  2.3 ± 1.8 0.012
No of good quality embryo 1.1 ± 0.7 0.90 ± 0.6 0.043
Transferred embryos (mean ± SD) 0.9 ± 0.8 0.7 ± 0.7 0.018
No. of cancelled cycles 13 (11.5%) 26 (10.8%) 0.841
Implantation 27 (46.6%) 58 (41.1%) 0.483
Clinical pregnancy 24 (41.4%) 48 (34.0%) 0.328
Live birth 17 (29.3%) 33 (23.4%) 0.383
Misscarriage 5 (21.7%) 8 (19.0%) 0.795
Multiple pregnancy 0 (0.0%) 4 (9.5%) 0.127
Values were presented as mean ± SD. P value < 0.05 was statistically significant. SD — 
standard deviation; BMI — body mass index; AFC — antral follicle count; AMH — anti-
mullerian hormone; FSH — follicle stimulating hormone; LH — luteinizing hormone; E2 — 
estradiol; P — progesterone; HCG — human chorionic gonadotropin; OPU — oocyte pick-
up; ET — embryo transfer; PN —Pronucleus
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Table 2. Comparison between the recFSH+HMG or recFSH treatment subpopulations of patients characterised by different ranges of AFC, < 4, 
4–6 and 7–10



















Age (Years) 32.4 ± 1.1 32.2 ± 1.2 0.234 32.8 ± 0.8 32.8 ± 1.1 0.419 32.4 ± 1 32.9 ± 1.1 0.131
BMI (kg/m2) 25.4 ± 4.3 26.2 ± 4.1 0.486 26.1 ± 7.1 26.6 ± 4.9 0.763 28.3 ± 5.2 26.3 ± 5.5 0.139
AFC 2.1 ± 0.9 2.6 ± 0.8 0.149 4.7 ± 0.7 5.4 ± 0.7 0.053 8.8 ± 0.9 9.1 ± 1.0 0.101
AMH 0.3 ± 0.2 0.4 ± 0.1 0.913 0.5 ± 0.2 0.5 ± 0.3 0.830 0.9 ± 0.1 0.9 ± 0.2 0.532
Days of stimulation 6.6 ± 2.9 7.9 ± 2.4 0.903 9 ± 1 9.3 ± 2
<
0.001
9.1 ± 1.7 9.9 ± 1.9 0.154






























P value on HCG day(pmol/l) 0.8 ± 0.2 0.7 ± 0.5 0.909 1 ± 0.8 0.8 ± 0.5 0.476 1 ± 0.5 2.2 ± 6 0.300
Endometrial thickness (mm) 
on HCG day
9.2 ± 1.1 9.5 ± 1.6 0.517 10.1 ± 2.9 9.5 ± 2.1 0.331 10 ± 2 10.1 ± 2.1 0.681
Number of follicles ≥ 17 mm 
in diameter on HCG day     1 ± 0.8
       1.5 ± 
1.2
0.398
     2.2 ± 1.3       2 ± 1.5
0.414
          3 ± 2     2.3 ± 1.5
0.035
Number of follicles 15–17mm 
in diameter on HCG day     0.7 ± 0.8       1.2 ± 1.3
0.440
     2.1 ± 1.7      1.8 ± 1.8
0.434
       2.8 ± 
2.6     2.2 ± 1.5
0.182
No. of retrieved oocytes 5.5 ± 3.5 2.9 ± 2.7 0.132 6.5 ± 1.7 4.4 ± 2.3 0.049 6.5 ± 2.2 6.3 ± 1.9 0.014
No. of mature oocytes 5 ± 2.8 1.8 ± 1.2 0.006 4.5 ± 2.6 3.2 ± 1.9 0.044 4.3 ± 2.5 5 ± 2 0.507
Fertilization rate (%) 0.7 ± 0 0.6 ± 0.5 0.432 0.6 ± 0.2 0.6 ± 0.4 0.315 0.5 ± 0.3 0.5 ± 0.3 0.356
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No. of 2PN 3.5 ± 2.1 1 ± 1.1 0.104 3 ± 0.8 2.2 ± 1.8 0.066 2.4 ± 1.7 2.8 ± 2.1 0.713
Implantation 3 (75.0%) 5 (41.7%) 0.248 2 (22.2%) 21 (47.7%) 0.160 21 (47.7%) 32 (37.6%) 0.270
Clinical pregnancy 2 (50.0%) 5 (41.7%) 0.771 2 (22.2%) 17 (38.6%) 0.349 12 (54.5%) 22 (35.5%) 0.155
Live birth 1 (25.0%) 3 (25.0%)
<
0.001
2 (22.2%) 11 (25.0%) 0.860 14 (31.8%) 19 (22.4%) 0.243
Misscarriage 1 (50.0%) 2 (40.0%) 0.809 0 (0%) 6 (35.3%) 0.310 4 (21.1%) 5 (20.0%) 0.932
Values were presented as mean ± SD. P value < 0.05 was statistically significant. SD — standard deviation; BMI — body mass index; AFC — 
antral follicle count; AMH — anti-mullerian hormone; FSH — follicle stimulating hormone; LH — luteinizing hormone; E2 — estradiol; P —  
progesterone; HCG — human chorionic gonadotropin; OPU — oocyte pick-up; ET — embryo transfer; PN — Pronucleus
Figure 1. Ovarian stimulation outcomes and comparison between the recFSH+HMG or recFSH treatment
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